3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
12
Terminated
2
Recruiting
2
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lymphoma, Follicular
6
Lymphoma
6
Multiple Myeloma
4
Neoplasms, Plasma Cell
3
Leukemia, Myeloid, Acute
3
Waldenstrom Macroglobulinemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Kidney Neoplasms
2
Immunoglobulin Light-chain Amyloidosis
2
Carcinoma, Renal Cell
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Unspecified Childhood Solid Tumor, Protocol Specific
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Interventions
Carboplatin
84
Cisplatin
79
Pemetrexed
72
Docetaxel
62
Drug Therapy
44
Gemcitabine
43
Erlotinib Hydrochloride
42
Gefitinib
38
Radiotherapy
36
Paclitaxel
36
pembrolizumab
31
Bevacizumab
29
icotinib
28
osimertinib
27
anlotinib
26
Nivolumab
26
camrelizumab
23
Vinorelbine
23
Radiosurgery
20
aumolertinib
18
atezolizumab
17
sintilimab
16
apatinib
16
Endostatins
16
endostar protein
15
durvalumab
14
Surgical Procedures, Operative
13
Immunotherapy
13
Immune Checkpoint Inhibitors
12
Blood Specimen Collection
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Non-Small-Cell Lung
×
sargramostim
×
Clear all
NCT03489616
2018-04-05
CRAGMOLC
Shandong Cancer Hospital and Institute
Phase NA
Unknown
45 enrolled